The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
innate pharma | 529 |
novo nordisk | 93 |
bristol-myers squibb company | 12 |
orega biotech | 5 |
innat farma | 2 |
innejt farma | 2 |
laboratoires mayoly spindler | 1 |
jac products | 1 |
innate pharmaceuticals | 1 |
inmate pharma | 1 |
innate pharma | 28 |
novo nordisk | 6 |
innat farma | 1 |
innate pharma | 62 |
novo nordisk | 3 |
bristol-myers squibb company | 2 |
orega biotech | 2 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies | 44 | 2003 |
monoclonal antibodies against nkg2a | 32 | 2004 |
methods and compositions for increasing the efficiency of therapeutic antibodies using n… 🛈 | 30 | 2003 |
antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use | 27 | 2003 |
neutralization of inhibitory pathways in lymphocytes | 23 | 2014 |
anti-kir antibodies for the treatment of inflammatory disorders | 22 | 2011 |
tlr3 binding agents | 17 | 2009 |
kir-binding agents and methods of use thereof | 16 | 2005 |
therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterp… 🛈 | 16 | 2004 |
nk cell modulating treatments and methods for treatment of hematological malignancies | 16 | 2010 |